News
Low-dose rituximab may keep RA disease activity low in responders
Rituximab doses as low as 200 mg were effective in treating rheumatoid arthritis, an extension study of a small trial in the Netherlands found.
News
Tofacitinib postmarketing trial data shed light on JAK inhibitor risks
Analyses of the phase 3b/4 ORAL Surveillance trial results found independent factors for risk for major adverse cardiovascular events, cancer, and...
News
For EGPA vasculitis, rituximab comparable with cyclophosphamide for inducing remission
A phase 3 trial has found that rituximab is not superior to cyclophosphamide to induce remission in eosinophilic granulomatosis with polyangiitis...
News
mRNA COVID vaccine response found mostly robust in RA, SLE patients
A trial found that immunosuppressed adults with autoimmune disease had a robust antibody response to the mRNA vaccine with no excess adverse...
News
Statins’ effects on CVD outweigh risk for diabetes in RA
A large cohort study reports that the cardiovascular benefits of statin use in people with rheumatoid arthritis outweigh the moderate diabetes...
News
Abatacept shows signal to delay onset of rheumatoid arthritis
Early results of a randomized clinical trial show that a 6-month course of abatacept may delay or prevent progression to rheumatoid arthritis.
News
AHA: Quality of STEMI care has stalled, needs improvement
A new American Heart Association policy statement recommends actions to improve care for people who have ST-segment elevation MI.
News
Study identifies pandemic-related stressor in Parkinson’s disease
Researchers in the Netherlands identified COVID-19–related stressors for people with Parkinson’s disease and the most vulnerable subgroups.
News
Investigative botulinum toxin formulation shows prolonged effect
A phase 3 trial reported that a new formulation of a botulinum toxin had a longer duration of effect with fewer side effects than existing...
News
Efforts target underrepresented populations in Parkinson’s disease genetic studies
Genetic studies in Parkinson’s disease have been heavily skewed to European populations, but a number of efforts aim to make study populations...
News
Synthetic triglyceride shows potential in Huntington’s disease
An extension study found that the synthetic medium-chain triglyceride triheptanoin improved brain energy and caudate atrophy in Huntington’s...
News
RA treatment responders show unique differences in gut microbiome
A cohort study found differences in the gut microbiome between patients with rheumatoid arthritis who improved clinically and those who did not....
News
Friedreich’s ataxia treatment shows extended benefit
An extension study of the Nrf2 activator omaveloxolone in people with Friedreich’s ataxia showed benefit out to more than 2 years.